GSK probing claims of improper conduct in Iraq
GlaxoSmithKline (GSK) has said it is investigating allegations of improper conduct in Iraq, nine months after China began a corruption probe into the local operations of the UK’s largest drugmaker, Bloomberg has reported. “These allegations relate to a small number of individuals,” the London-based company said. “However, we are investigating whether there has been any improper conduct. We have zero tolerance for unethical or illegal behaviour.” In Iraq, Glaxo hired 16 government-employed doctors and pharmacists as paid sales representatives, the Wall Street Journal reported, citing e-mails from an unidentified person familiar with Glaxo’s Mideast operations. Glaxo’s pharmaceutical operations employ fewer than 60 people in Iraq, according to the company.